Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00807339 · ClinicalTrials.gov registry record · NA
CyberKnife for Unresectable Renal Tumors
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT00807339 is a NA study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 17 participants.
The verdict
NCT00807339, a NA study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a dose escalation study using the CyberKnife radiotherapy device for small surgical or medically untreatable renal tumors. Patients with renal tumors 5cms or less in diameter will be accrued onto this study. The ability of CyberKnife to ablate these renal tumors and maintain renal function with dose escalation will be assessed.
Interventions
- RADIATION Stereotactic radiation
- DEVICE CyberKnife Robotic Radiosurgery System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2006-03 |
| Est. Completion | 2014-08-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00807339
The ClinicalTrials.gov registry entry for NCT00807339 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stereotactic radiation is the first listed.
NCT00807339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00807339 about?
NCT00807339 is a clinical study titled "CyberKnife for Unresectable Renal Tumors". This is a dose escalation study using the CyberKnife radiotherapy device for small surgical or medically untreatable renal tumors. Patients with renal tumors 5cms or less in diameter will be accrued onto this study. The ability of CyberKnife to ablate these renal tumors and maintain renal function w...
What is the current status of trial NCT00807339?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2006-03. Estimated completion is 2014-08-20.
What interventions are being tested in trial NCT00807339?
The interventions under investigation include: Stereotactic radiation (RADIATION), CyberKnife Robotic Radiosurgery System (DEVICE).
Who is sponsoring clinical trial NCT00807339?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.